Please login to the form below

Not currently logged in
Email:
Password:

drug side effects

This page shows the latest drug side effects news and features for those working in and with pharma, biotech and healthcare.

AbbVie signs immunotherapy pact with I-Mab worth $2bn

AbbVie signs immunotherapy pact with I-Mab worth $2bn

In addition, I-Mab will receive a milestone payment of $20m based on results from phase 1 studies of the drug. ... Lemzoparlimab is designed to minimise binding to normal red blood cells while also demonstrating strong anti-tumour activity, which helps

Latest news

  • Nektar’s opioid analgesic slammed with FDA panel rejection Nektar’s opioid analgesic slammed with FDA panel rejection

    High levels of euphoric side-effects from opioid medications have lead to abuse and addiction, which has caused a healthcare crisis to erupt across the US. ... Nektar’s drug avoids these side-effects because – according to the company – its

  • FDA clears SK Life Science’s anti-epileptic drug Xcopri FDA clears SK Life Science’s anti-epileptic drug Xcopri

    Significantly reduced the frequency of seizures at all doses studied. Korea-based SK Life Sciences has scored approval from the FDA in the US for its anti-epileptic drug Xcopri, as ... The safety profile of the anti-epilepsy drug does include side

  • Servier faces manslaughter trial over weight loss drug deaths Servier faces manslaughter trial over weight loss drug deaths

    Lawyers representing the 2, 684 plaintiffs claim that Servier and the ANSM allowed the drug to remain on the market even though its side effects had been known for several years, ... The side effects caused by Mediator were uncovered by French

  • Tecfidera successor’s side-effect profile boosts Biogen Tecfidera successor’s side-effect profile boosts Biogen

    One of the biggest issues is that these newer treatments don’t cause the gastrointestinal side-effects frequently seen in patients taking Tecfidera. ... However, that’s not to say patients on the new drug were without side-effects: the most common

  • ViiV builds case for switching to its two-drug HIV combinations ViiV builds case for switching to its two-drug HIV combinations

    The TANGO study is intended to show that people with HIV can reduce the number of medicines in their HIV treatment regimen, potentially reducing the risk of side effects and drug ... Injectable option. Meanwhile, ViiV also had an update this week on

More from news
Approximately 1 fully matching, plus 108 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Much of this research centred on improving the selectivity of compounds so that they hit the target, M1, without also interacting with similar receptors linked to the intolerable side effects. ... Meanwhile, Karuna Pharmaceuticals has raised $42m to

  • Redirecting your patient strategy Redirecting your patient strategy

    But when people are dealing with their condition for so long, it is important that you understand how they're actually managing it, how they're using the drug.”. ... These new companies have developed novel business models based on sharing the data and

  • Choices, choices: the rapidly evolving HIV treatment landscape Choices, choices: the rapidly evolving HIV treatment landscape

    IIs are more potent, with fewer side effects and drug interactions and the top reason for prescribing them is their good tolerability profile. ... As patients differ so do their barriers to adherence, whether this be complexity of the dosing regimen,

  • Patients First Patients First

    to their thoughts on the impact of drug side effects, these are all areas that pharma is already actively engaged with at some level.

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    The G-BA assesses drugs on four criteria: mortality; morbidity (for example, symptom improvement); quality of life; and adverse events (toxicity and side effects). . ... A natural question to ask is how the benefit finding impacts the final price of a

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics